The MedAdvisor (ASX:MDR) share price is lifting today. Here's why

The MedAdvisor (ASX: MDR) share price is surging today after a health program deal was extended. Here are the details.

The MedAdvisor Ltd (ASX: MDR) share price is soaring today after the company announced an extension of a health program deal.

In early afternoon trade, the medication management platform provider's shares are swapping hands for 33.5 cents, up 3.8% after reaching an intraday high of 35 cents.

Let's take a closer look at what's driving the MedAdvisor share price higher today.

Three pills with faces showing sad to happy, indicating a rising share price for an ASX pharmaceutical company

Image source: Getty Images

Health program extension

In its release, MedAdvisor advised that a global pharmaceutical company has extended its United States health program deal for an estimated additional 3 months. The contract extension is expected to generate US$4.7 million in revenue for MedAdvisor.

This follows a previously signed agreement that saw MedAdvisor provide its platform to the pharmaceutical company over a 5-month period. That deal alone was worth US$3.7 million.

Although MedAdvisor did not specify which company was behind the contract extension, it is believed to be from a top 10 global pharmaceutical company.

Words from management

MedAdvisor CEO and managing director Robert Read hailed the company's success, saying:

We're delighted to have another health program extended in the US market. These health programs deliver tailored content specifically to the right patients based on advanced algorithms and are designed to ensure they are aware of the benefits of certain medications or vaccines.

MedAdvisor continues to expand its global deal pipeline as it establishes scalable revenue streams both domestically and abroad. Our US pipeline of 2021 deals is ahead of this time last year.

MedAdvisor share price snapshot

The MedAdvisor share price hasn't moved much over the last 12 months, rising a modest 6%. Its year-to-date performance, however, is marginally down around 2%.

MedAdvisor shares reached a multi-year high of 66.5 cents in late May 2020 before treading lower.

Based on valuation grounds, the company commands a market capitalisation of more than $124 million, with 359.4 million shares outstanding.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MedAdvisor. The Motley Fool Australia has recommended MedAdvisor. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »